London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
CBDBULL why bother going to all that trouble to create a new profile ! Truly Pathetic!
The lads are finally scratching Dr Nadya Lisovoder's back. I guess some favourable Flaskdata is in order.
Nice of them to only nibble on shareholder's ass' via diluting over 12months vs. taking a satisfying bite.
Tin rattle coming next month?
Just pasted the Ann. Smartic ;-)
I think 4 of 5 are a step ahead of Irontool.
Great rns, chart is steady setting higher lows. This is a bigger deal than people seem to realise. It will catch people out in the coming months. IMO.
Jetjock agree this should be rerated after excellent acquisition RNS, 10% sellers will regret but thanks to short termers gives chance to topup...GLA
Lovely sea of blue
100%, I'm all for it
Must say, @Archie, I do feel that giving the shares is a better consideration than giving out MGC cash at this point.
Amazed it hasn’t risen significantly on this news..
CEO of the acquired company, Dr Nadya Lisovoder, is listed in the MGC Pharma prospectus as a clinical advisor. Is this likely to be a good thing, showing an existing working relationship between the parties and smooth moving forward? Feels a little off that more MGC money/equity is moving to insiders' other companies.
I read in the article that they are paying this company with $6,000,000 worth of shares. That is also quite positive for us as this company must feel that they are going to be worth something in the future. Adds even more confidence for me in this company.
Acquisition payments are instalment over the next few months
Does this mean a further fund raise required to raise the capiital in near future?
Excellent buy - bringing more parts of the jigsaw in-house plus profitable revenues from other trial processes - I'm liking MGC more and more - great medium/long term hold
On the face of it this appears a logical and beneficial move. Planning ahead, Go big or go home.
It’s a genius move. It will greatly speed up the approval process, save 3rd party costs, boost revenue and the company they are acquiring makes a profit!
Well found smlfry
One step ahead of IRONBOY must grate him that he has to copy your info and research when he slates you on here just shows who is on the ball
MGC Pharma to acquire Israeli clinical and medical research company, MediCaNL
Key Highlights:
• MGC Pharma to acquire 100% of worldwide pharmaceutical clinical research company,
MediCaNL Inc (MCL).
• On completion of the acquisition, MediCaNL will design, manage and run all clinical trials for
MGC Pharma in accordance with the European Medicines Agency, Federal Drug
Administration, ICH Good Clinical Practice and Israeli health regulations.
• The MediCaNL acquisition will deliver significant and immediate cost savings to the Company.
• MediCaNL will become an internal business unit running at cost only for MGC Pharma,
eliminating the retail operating margins being paid to third party CRO providers on all future
clinical trials, as MGC Pharma will be undertaking multiple clinical trials in 2021/22 and in
future years.
• Two Phase I and Phase II clinical trials and one Phase III clinical trial planned to be undertaken
by MGC Pharma in 2021 alone for CannEpil, CogniCann and CimetrA.
• MediCaNL currently have 11 clients (excluding MGC Pharma) with 40 ongoing projects,
including clinical trials as well as involvement in seven Investigational New Products (INP),
with two approved by the FDA and four in progress.
• MediCaNL generated approximately $1 million in revenues in 2020 with a 25% profit margin.
• Transaction terms including consideration of AU$6 million in MXC shares, 30% on settlement
and 70% in instalments as deferred consideration (following shareholder approval).
• Acquisition leverages the medical research expertise in-house which significantly reduces
preclinical lead times, provides the ability to better define clinical trial protocols and builds
stronger relationships with regulators moving forward.